Ruti Aga's six-year ban: the heavier sentence was written on a fake prescription

A prescription written on an old pad, signed by someone with no medical licence, issued by a clinic that does not exist. Those three details, added together, cost more than a positive test.

On 10 September, the Athletics Integrity Unit (AIU) — World Athletics' independent integrity body — announced a six-year ban for Ruti Aga, the Ethiopian marathoner who won the 2026 Tokyo Marathon. The sanction splits into two parts: two years for the presence of methylprednisolone in her sample, and four years for tampering with evidence during results management. The two parts are served consecutively, not concurrently.

I have a habit of counting things nobody counts: articles published, cameras present, spectators in the stands. It began at a provincial women's football final in 2026, where I sat in the third row and counted 127 people. Nobody wrote about that final, so I wrote it. Reading Aga's decision, I counted something else: years. Two plus four. Six.

To understand the six, the substance has to be named precisely. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid, commonly used for joint inflammation, soft-tissue injury and allergic reaction. It sits in WADA class S9, prohibited in-competition only, and it is a Specified Substance: a category recognised as more plausibly linked to therapeutic or inadvertent use. Many reports called it a steroid, which points readers toward the anabolic-androgenic family and a completely different performance logic. Aga said she used it to treat a knee injury. If that is accurate, this is ordinary medical life for someone who runs 42 kilometres.

The positive sample came from a half marathon in China in March. Within the economics of East African road running, that is a familiar template: Asian road races pay appearance fees, invite Kenyan and Ethiopian athletes, and run on a much thinner scrutiny budget than a World Marathon Major. The race time was not disclosed, so I am not comparing it with her personal best. Where the data stops, I stop.

What deserves analysis is the arithmetic of the sanction.

Under the WADA Code, multiple anti-doping rule violations are served consecutively. The baseline for presence of a Specified Substance, absent proof of intent, is two years. The baseline for tampering — falsifying evidence during results management — is four years. The AIU applied both, then added them.

The penalty for the fake prescription was twice the penalty for the prohibited substance. Across the whole file, the medical half was the softest half; the administrative half was the lethal one.

There is a reason for that. The Specified Substance category exists to protect athletes who make genuine treatment errors. An athlete with an inflamed knee, given a corticosteroid injection, may face no violation at all if a valid TUE is in place or if the route and timing fall outside the in-competition window. Even the worst realistic outcome of an honest disclosure about a treatment mistake tends to land below two years.

Aga did not take that route. She submitted a prescription. And the prescription collapsed in the standard way of the data era: the AIU verified directly with the clinic, checked the practitioner's registration number, cross-referenced the staff list. The clinic said the prescription was not theirs. The signatory had never worked there. The old prescription pad saved nobody.

The real cost of the arithmetic sits in the age column. Aga was 32 when the ban took effect. For female marathoners, the peak window commonly extends to 35 and beyond. She was at the peak, not past it. Six years returns her at roughly 38, after a layoff longer than any injury absence in the sport. Competitively, this is a career-ending sanction rather than a suspension.

Financially the mechanism is just as clear: the March half marathon result is almost certainly annulled and the prize money forfeited, and for six years the two core revenue streams of an elite marathoner — appearance fees and World Marathon Majors invitations — disappear. She won Tokyo in 2026 and finished runner-up at three Majors. That record places her in the world's elite tier of women's road running for the 2026–2026 window. No mechanism restores the market value of that record after a tampering ban.

Most headlines will say doping. I think that reading misses the most important point.

With only the positive test, this is a medical story — sad, forgivable in public perception, mitigable in the file. What moved the case to another floor was how it was handled: a family member signing, a clinic invented, a prescription pad borrowed from a former workplace. This is amateur forgery, and the amateurism is itself diagnostic: nobody around Aga had the legal and medical competence to tell her that a late TUE is better than a fake prescription.

I have spent years looking at the support structures around female athletes in thin road-running systems. In an 18m² room, I watched 52 matches and a revolution — but that revolution was tactical, on the field. Off it, most East African distance runners still manage their own medical paperwork, often through relatives, often verbally, often without a lawyer. When that system meets an organised verification process, it breaks.

The second counter-intuitive point: this is not evidence of systemic Ethiopian doping. Aga is a replaceable node in a pipeline that is far too deep. Ethiopia loses her and the competitive balance of women's marathon barely moves. The real loss is to the reputational premium of the Ethiopian road-running brand — which matters to agents, organisers and sponsors — not to the results board.

The third point is one I would ask newsrooms to handle carefully: calling methylprednisolone an anabolic steroid inflates perceived severity for general readers. A corticosteroid for a knee and an anabolic cycle for muscle mass are different stories physiologically and ethically. Blending them is a form of misinformation that simply goes unchecked.

One more detail rarely placed alongside the others: the race that produced the positive sample was in China. The Asian road circuit, built on appearance fees, concentrates East African athletes in high-volume, low-scrutiny races that few people write about. Where the sample is taken and where the story is told are usually not the same place. The score 1,937–63 does not sit on the grass; it sits on the sports pages.

Six years for a fake prescription. I do not find the sanction unjust. I find it cold.

What bothers me is elsewhere: the anti-doping system is good enough to detect a non-existent clinic within days, yet has no mechanism to give a 32-year-old athlete a free consultation before she stamps her own career shut. She does not need a status. She needs a seat that gets written about — and in this case, someone sitting beside her saying: do not submit that paper.

Women's marathon will continue. Aga will not. If an athlete has no lawyer, no team doctor, no one to read her file, does the sanction measure her fault — or the size of the hole in the system?